Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

Giuseppe Derosa, Antonio V. Gaddi, Mario N. Piccinni, Leonardina Ciccarelli, Sibilla Salvadeo, Emmanouil Peros, Morena Ghelfi, Ilaria Ferrari, Arrigo F G Cicero

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Study Objective. To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome. Design. Multicenter, double-blind, randomized, controlled trial. Setting. Two university-affiliated medical centers in Italy. Patients. Ninety-five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome. Intervention. All 95 patients received metformin 1500 mg/day. In a randomized manner, 47 patients received glimepiride 2 mg/day and 48 patients received rosiglitazone 4 mg/day. Measurements and Main Results. Body mass index (BMI), glycemic control, and coagulation and fibrinolysis parameters were evaluated at 3, 6, 9, and 12 months of treatment. Compared with baseline values, significant decreases in BMI, fasting plasma glucose, postprandial plasma glucose, and hemoglobin A1c were observed at 12 months in both the glimepiride and rosiglitazone groups (p

Original languageEnglish
Pages (from-to)637-645
Number of pages9
JournalPharmacotherapy
Volume25
Issue number5 I
DOIs
Publication statusPublished - May 2005

Fingerprint

rosiglitazone
glimepiride
Metformin
Type 2 Diabetes Mellitus
Fibrinolysis
Glucose
Body Mass Index
Therapeutics
Hypoglycemic Agents
Italy
Fasting
Hemoglobins
Randomized Controlled Trials

Keywords

  • Antithrombotic effects
  • Combination therapy
  • Glimepiride-metformin
  • Metabolic syndrome
  • Rosiglitazone-metformin
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. / Derosa, Giuseppe; Gaddi, Antonio V.; Piccinni, Mario N.; Ciccarelli, Leonardina; Salvadeo, Sibilla; Peros, Emmanouil; Ghelfi, Morena; Ferrari, Ilaria; Cicero, Arrigo F G.

In: Pharmacotherapy, Vol. 25, No. 5 I, 05.2005, p. 637-645.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Gaddi, Antonio V. ; Piccinni, Mario N. ; Ciccarelli, Leonardina ; Salvadeo, Sibilla ; Peros, Emmanouil ; Ghelfi, Morena ; Ferrari, Ilaria ; Cicero, Arrigo F G. / Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. In: Pharmacotherapy. 2005 ; Vol. 25, No. 5 I. pp. 637-645.
@article{b72d15682dba43c9829463f26d3e4315,
title = "Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome",
abstract = "Study Objective. To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome. Design. Multicenter, double-blind, randomized, controlled trial. Setting. Two university-affiliated medical centers in Italy. Patients. Ninety-five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome. Intervention. All 95 patients received metformin 1500 mg/day. In a randomized manner, 47 patients received glimepiride 2 mg/day and 48 patients received rosiglitazone 4 mg/day. Measurements and Main Results. Body mass index (BMI), glycemic control, and coagulation and fibrinolysis parameters were evaluated at 3, 6, 9, and 12 months of treatment. Compared with baseline values, significant decreases in BMI, fasting plasma glucose, postprandial plasma glucose, and hemoglobin A1c were observed at 12 months in both the glimepiride and rosiglitazone groups (p",
keywords = "Antithrombotic effects, Combination therapy, Glimepiride-metformin, Metabolic syndrome, Rosiglitazone-metformin, Type 2 diabetes",
author = "Giuseppe Derosa and Gaddi, {Antonio V.} and Piccinni, {Mario N.} and Leonardina Ciccarelli and Sibilla Salvadeo and Emmanouil Peros and Morena Ghelfi and Ilaria Ferrari and Cicero, {Arrigo F G}",
year = "2005",
month = "5",
doi = "10.1592/phco.25.5.637.63587",
language = "English",
volume = "25",
pages = "637--645",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5 I",

}

TY - JOUR

T1 - Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome

AU - Derosa, Giuseppe

AU - Gaddi, Antonio V.

AU - Piccinni, Mario N.

AU - Ciccarelli, Leonardina

AU - Salvadeo, Sibilla

AU - Peros, Emmanouil

AU - Ghelfi, Morena

AU - Ferrari, Ilaria

AU - Cicero, Arrigo F G

PY - 2005/5

Y1 - 2005/5

N2 - Study Objective. To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome. Design. Multicenter, double-blind, randomized, controlled trial. Setting. Two university-affiliated medical centers in Italy. Patients. Ninety-five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome. Intervention. All 95 patients received metformin 1500 mg/day. In a randomized manner, 47 patients received glimepiride 2 mg/day and 48 patients received rosiglitazone 4 mg/day. Measurements and Main Results. Body mass index (BMI), glycemic control, and coagulation and fibrinolysis parameters were evaluated at 3, 6, 9, and 12 months of treatment. Compared with baseline values, significant decreases in BMI, fasting plasma glucose, postprandial plasma glucose, and hemoglobin A1c were observed at 12 months in both the glimepiride and rosiglitazone groups (p

AB - Study Objective. To evaluate the differential effect on coagulation and fibrinolysis parameters of combination therapy with glimepiride-metformin and with rosiglitazone-metformin beyond their effect on glucose metabolism in patients with type 2 diabetes and metabolic syndrome. Design. Multicenter, double-blind, randomized, controlled trial. Setting. Two university-affiliated medical centers in Italy. Patients. Ninety-five patients with type 2 diabetes for at least 6 months without glycemic control by diet and oral hypoglycemic agents to their maximum tolerated dosage and who also had metabolic syndrome. Intervention. All 95 patients received metformin 1500 mg/day. In a randomized manner, 47 patients received glimepiride 2 mg/day and 48 patients received rosiglitazone 4 mg/day. Measurements and Main Results. Body mass index (BMI), glycemic control, and coagulation and fibrinolysis parameters were evaluated at 3, 6, 9, and 12 months of treatment. Compared with baseline values, significant decreases in BMI, fasting plasma glucose, postprandial plasma glucose, and hemoglobin A1c were observed at 12 months in both the glimepiride and rosiglitazone groups (p

KW - Antithrombotic effects

KW - Combination therapy

KW - Glimepiride-metformin

KW - Metabolic syndrome

KW - Rosiglitazone-metformin

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=18044390662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044390662&partnerID=8YFLogxK

U2 - 10.1592/phco.25.5.637.63587

DO - 10.1592/phco.25.5.637.63587

M3 - Article

C2 - 15899724

AN - SCOPUS:18044390662

VL - 25

SP - 637

EP - 645

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5 I

ER -